Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: trastuzumab
DATE: 28/02/2019
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
PRIVACY POLICY
SUBSCRIBE
